Advanced Filters
noise

Mild Cognitive Impairment Clinical Trials

A listing of Mild Cognitive Impairment medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 284 clinical trials
X Xiaoyun Yang, Dr

Treatment and Clinical Outcomes Among SLE Patients in Pregnancy

Systemic lupus erythematosus (SLE) is a kind of systemic autoimmune disease which can cause multiple organs and system damage, which often occurs in women of childbearing age. Compared with healthy pregnant women, SLE patients have higher incidence of premature delivery, preeclampsia and fetal loss during pregnancy. Since SLE patients usually …

20 - 45 years of age Female Phase 1
A Alexandra Freeman, M.D.

Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis

Background Autosomal dominant hyper-IgE syndrome (HIES), also called Job syndrome, is a genetic disorder that affects the immune system. It can cause skin and lung infections and problems with blood vessels, connective tissues, and bones. People with HIES often have lupus-like disease or atopic dermatitis (skin rash). Researchers want to …

12 - 120 years of age All Phase 1
I Ioannis Parodis, MD PhD | Associate Professor

Per-protocol Repeat Kidney Biopsy in Incident Cases of Lupus Nephritis

Lupus nephritis (LN) is one of the most severe complications of systemic lupus erythematosus (SLE). Among people living with SLE, 35-60% will develop LN during the course of the disease. This complication is one of the factors that contribute to deterioration of the renal function. Some centres perform kidney biopsies …

18 years of age All Phase N/A

RY_SW01 Cell Injection Therapy in Active Lupus Nephritis

RY_SW01 Cell Injection's preclinical research results have shown that the injection significantly improved urine biochemical indicators and tissue damage in two lupus nephritis animal models after MSC administration, with no occurrence of rejection and excellent safety. The mechanism of action of RY_SW01 Cell Injection is relatively clear, demonstrating favorable therapeutic …

18 - 65 years of age All Phase 2
B Bogdan Obrisca, MD, PhD

Minimizing Glucocorticoid Administration in Patients With Proliferative Lupus Nephritis

The aim of the study is to evaluate the efficacy of a therapeutic regimen which decreases glucocorticoid exposure compared with standard therapy in patients with proliferative lupus nephritis during remission induction by evaluating the histological and clinical remission.

18 - 80 years of age All Phase 4

A Study of Telitacicept in Lupus Nephritis

The purpose of this study is to evaluate the safety and efficacy of Telitacicept in adult patients with active lupus nephritis.

18 - 75 years of age All Phase 2
W Wenqiang Fan

Phase IIa Study for IPG11406 in Patients With Lupus Nephritis

A multi-center, multi-dose phase Ib/IIa clinical study evaluating the safety, tolerability, preliminary efficacy, pharmacokinetics, and impact on biomarkers of IPG11406 in patients with Lupus Nephritis

18 - 70 years of age All Phase 1/2
A Audrey Stratemeyer

VIBRANT: VIB4920 for Active Lupus Nephritis

This is a multi-center double-blind placebo controlled clinical trial evaluating the efficacy of VIB4920 combined with mycophenolate mofetil (MMF) and prednisone in achieving a renal response in participants with active lupus nephritis (LN).

18 years of age All Phase 2

A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis

The purpose of this study is to assess the efficacy of QL1074 compared with placebo in achieving renal response after 52 weeks of therapy in subjects with Active Lupus Nephritis.

18 - 75 years of age All Phase 3
X Xia Gao, M.D.

Chimeric Antigen Receptors T Cells for Refractory/Recurrent Lupus Nephritis in Children

The goal of this prospective, open, single-arm clinical trial was to evaluate the safety and potential efficacy of CAR T cell therapy in children with refractory/recurrent lupus nephritis. The persistence and cell phenotype of CAR-T cells in vivo and CAR-T treatment-related inflammatory factors were evaluated after treatment. To explore new …

6 - 18 years of age All Phase 3

Simplify language using AI